Health & MedicineTop StoryTop StoryLatest News
Pomegranate-Linked Compound Shows Promise for Heart Failure Treatment, King’s College London Study Finds
A study from King’s College London reveals that urolithin A, derived from pomegranates, can enhance heart function by up to 80% in animal models, offering hope for heart failure patients.
Confidence: 90%Sentiment: NeutralHigh Priority
What Happened?
A study from King’s College London reveals that urolithin A, derived from pomegranates, can enhance heart function by up to 80% in animal models, offering hope for heart failure patients.
AI Quick Summary
A study shows urolithin A from pomegranates can significantly improve heart function in animal models, raising hopes for heart failure treatments.
Key points
- Urolithin A improves heart function by up to 80% in animal studies.
- The compound helps the heart relax, reduces scarring, and prevents enlargement.
- It could benefit patients with heart failure with preserved ejection fraction (HFpEF).
- Current treatments for HFpEF are limited and focus on managing underlying conditions.
- The study suggests dietary approaches may enhance urolithin A production.
Key insights
- The findings may lead to new therapeutic targets for heart failure treatment.
- Urolithin A's activation of PKGIα could improve heart muscle relaxation.
- Further clinical trials are necessary to confirm effectiveness in humans.
Why it matters
This research could lead to new treatments for heart failure, a condition affecting many people.
Source
Times Now
